| __timestamp | CymaBay Therapeutics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 9335772 |
| Thursday, January 1, 2015 | 8871000 | 12390000 |
| Friday, January 1, 2016 | 9645000 | 25602000 |
| Sunday, January 1, 2017 | 12387000 | 21262000 |
| Monday, January 1, 2018 | 14381000 | 28430000 |
| Tuesday, January 1, 2019 | 19238000 | 40849000 |
| Wednesday, January 1, 2020 | 17425000 | 60210000 |
| Friday, January 1, 2021 | 23040000 | 83664000 |
| Saturday, January 1, 2022 | 25116000 | 104097000 |
| Sunday, January 1, 2023 | 51953000 | 106916000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, CymaBay Therapeutics, Inc. and Iovance Biotherapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Iovance's SG&A expenses surged by over 1,000%, peaking at approximately $107 million in 2023. In contrast, CymaBay's expenses increased by around 535%, reaching nearly $52 million in the same year. This stark difference highlights Iovance's aggressive expansion strategy compared to CymaBay's more measured approach. Notably, both companies experienced their most significant expense growth between 2021 and 2023, reflecting broader industry trends. As these companies continue to innovate, monitoring their financial strategies will provide insights into their future market positions.
Comparing SG&A Expenses: AstraZeneca PLC vs CymaBay Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: AstraZeneca PLC vs Iovance Biotherapeutics, Inc.
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Dr. Reddy's Laboratories Limited and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Amneal Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?